180 related articles for article (PubMed ID: 21739169)
1. Prophylactic intrathecal chemotherapy in primary CNS lymphoma.
Sierra Del Rio M; Ricard D; Houillier C; Navarro S; Gonzalez-Aguilar A; Idbaih A; Kaloshi G; Elhallani S; Omuro A; Choquet S; Soussain C; Hoang-Xuan K
J Neurooncol; 2012 Jan; 106(1):143-6. PubMed ID: 21739169
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
Hoang-Xuan K; Taillandier L; Chinot O; Soubeyran P; Bogdhan U; Hildebrand J; Frenay M; De Beule N; Delattre JY; Baron B;
J Clin Oncol; 2003 Jul; 21(14):2726-31. PubMed ID: 12860951
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
Illerhaus G; Marks R; Müller F; Ihorst G; Feuerhake F; Deckert M; Ostertag C; Finke J
Ann Oncol; 2009 Feb; 20(2):319-25. PubMed ID: 18953065
[TBL] [Abstract][Full Text] [Related]
7. A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.
Taoka K; Okoshi Y; Sakamoto N; Takano S; Matsumura A; Hasegawa Y; Chiba S
Int J Hematol; 2010 Nov; 92(4):617-23. PubMed ID: 20967518
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.
Makino K; Nakamura H; Hide T; Kuroda J; Yano S; Kuratsu J
Int J Clin Oncol; 2015 Feb; 20(1):29-34. PubMed ID: 24722885
[TBL] [Abstract][Full Text] [Related]
10. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
[TBL] [Abstract][Full Text] [Related]
12. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
[TBL] [Abstract][Full Text] [Related]
13. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
[TBL] [Abstract][Full Text] [Related]
14. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
15. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
16. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
[TBL] [Abstract][Full Text] [Related]
17. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
Cortes J; O'Brien SM; Pierce S; Keating MJ; Freireich EJ; Kantarjian HM
Blood; 1995 Sep; 86(6):2091-7. PubMed ID: 7662956
[TBL] [Abstract][Full Text] [Related]
18. Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma.
Seidel S; Pels H; Schlömer S; Kowoll A; Fliessbach K; Engert A; Vogt-Schaden M; Egerer G; Reichmann H; Schackert G; Kroschinsky F; Deckert M; Herrlinger U; Klockgether T; Fimmers R; Bode U; Schmidt-Wolf IGH; Schlegel U
Neurology; 2020 Dec; 95(23):e3138-e3144. PubMed ID: 32989105
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.
Omuro AM; DeAngelis LM; Yahalom J; Abrey LE
Neurology; 2005 Jan; 64(1):69-74. PubMed ID: 15642906
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
